Science

ALDH FAMILY

Aldehyde Dehydrogenases (ALDHs) belong to a family of enzymes that play a key role in the metabolism of endogenous and exogenous aldehydes. This group of intracellular enzymes plays a pivotal role in embryogenesis and cell differentiation as well as in cancer progression by mediating retinoic acid signalling. Their functional activity also extends to cellular redox homeostasis via detoxification of reactive aldehydes derived from lipid peroxidation and other metabolic processes thus, playing a major cytoprotective role in cells.

 

Read more

MECHANISM OF ACTION

ABD-3001 A FIRST-IN-CLASS INHIBITOR

ABD-3001 is a suicidal inhibitor of ALDH1 and 3. It blocks the enzyme activity irreversibly causing rapid accumulation of reactive aldehydes in tumour cells, beyond critical threshold. The accumulated aldehydes, notably HNE and MDA form genotoxic adducts with protein and DNA affecting the oncogenic signalling pathways that participate in cell proliferation.

 

Read more

Our vision

Advanced Biodesign

Based on our expertise in cancer metabolism and know-how in specific cell death called “apoptosis”, we will develop a new way to treat cancer to overcome actual stratification of cancer to bring new hope for patient.  By focusing on rare or bad-prognostic cancer, Advanced BioDesign offer innovative therapy to target markets with high unmet medical needs in cancer.  

News

In the press: Interview in Biotech.info

Ismail CEYLAN, CEO of Advanced BioDesign was interviewed for Biotech.info about our First-In-Man clinical trial ODYSSEY.

Read more
Advanced Biodesign receives authorization from ANSM for its “ODYSSEY” Clinical Trial in Acute Myeloid Leukaemia

ODYSSEY is the Phase I First-in-Human clinical trial of drug candidate ABD-3001 in Acute Myeloid Leukaemia (AML) Lyon, 26th January 2022 – Advanced BioDesign, a French biotechnology company specializing in the development of a new group of targeted cancer therapies, has announced that it has received authorization from ANSM (National Agency for Medicinal Safety) and from the CPP (Committee for People Protection) to start its first clinical trial phase for its drug candidate ABD-3001 (a clinical formulation of DIMATE), in Acute Myeloid Leukaemia (AML) and in patients with Myelodysplastic Syndrome (MDS). AML is one of the most common leukaemia among adults, with an occurrence rate in Western countries between 3.7 and 6 per 100,000 inhabitants. Today, the 5-year survival rate among patients over the age of 20 is around 25%, a figure which illustrates the unmet medical needs in this indication.

Read more